Cartesian Therapeutics Inc. (RNAC) Stock Analysis

Cartesian Therapeutics Inc. (RNAC) is a publicly traded company in the HEALTHCARE sector. It trades at $6.41, carries a market capitalization of $203.32M. This page summarizes the public market data, fundamentals, and frequently asked questions for RNAC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cartesian Therapeutics Inc. currently has a Bullish sentiment score of 0.32.

About Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc. (ticker: RNAC) is a leading clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializing in the development of breakthrough nanoparticle immunomodulatory therapeutics. The company is at the forefront of addressing critical unmet medical needs through its innovative drug platform, which aims to enhance immune responses across various therapeutic areas. With a diverse pipeline of advanced biotherapeutics currently under clinical evaluation...

GNG Research Analysis

GNG Research scores Cartesian Therapeutics Inc. (RNAC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for RNAC.

Frequently Asked Questions

Does RNAC pay dividends?

Cartesian Therapeutics Inc. (RNAC) does not currently pay a regular dividend.

What is RNAC's market cap?

Cartesian Therapeutics Inc. (RNAC) has a market capitalization of $203.32M with a current stock price of $6.41.